A clinical study to see the effect of an Ayurvedic formulation in comparison with Olopatadine (0.1%) Eye Drop in allergic conjunctivitis

An Open Labeled Randomized Controlled Clinical Trial to Evaluate Efficacy Of Kantakari Mula Siddha Kshira Ghrita Aschyotana And Olopatadine (0.1%) Eye Drop in Vataja Abhishyanda.

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/018185

Enrollment

Registered

2019-03-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H10- Conjunctivitis

Interventions

Intervention1: Kantakarimula Siddha Kshira Ghrita Aschyotan: Combination of Bharad of Kantakarimula, Ajadugdha, Goghrita. The drug will be prepared by snehasiddhi kalpana. Dose-1drop Frequency- Twice

Eligibility

Inclusion criteria

Inclusion criteria: Patients suffering from Vataja Abhishyanda shows Toda, Sangharsha, Shishirashruta, Alpa Shopha. 2)Age 18-60yrs, Gender- Male and Female. 3)Only those cases will be accepted for final assessment who successfully complete the treatment in given time.

Exclusion criteria

Exclusion criteria: 1)Pittaja, Kaphaja, Raktaja Abhishyanda. 2)Other ocular complications such as Corneal Opacity, Corneal Ulcer. 3)Patient suffering from other systemic disease such as Bronchial Asthma, Allergic Bronchitis, Dermatitis, Allergic Rhinitis, DM, HTN.

Design outcomes

Primary

Measure	Time frame
Effect of Kantakarimula siddha Kshira Ghrita Aschyotan as compared to Olopatadine 0.1% eye drop in Vataj Abhishyanda.Timepoint: Effect of Kantakarimula siddha Kshira Ghrita Aschyotan as compared to Olopatadine 0.1% eye drop in Vataj Abhishyanda.	—

Secondary

Measure	Time frame
Antihistaminic effect of Kantakarimula siddha Kshira GhritaTimepoint: 18 months	—

Countries

India

Contacts

Public ContactDr Pravin M Bhat

MAMs Sumatibhai Shah Ayurved College

vdpravin82@gmail.com9860233173

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026